Abstract
BackgroundRheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have